


**PATIENT**

Finley Clancy

**PRESENTING CLINICAL SIGNS**

 History: Recheck echo. Doing well. BP: 190, 195mmHg.  
 -Current medications: Vetmedin, meloxicam, hepato support.  
 -Pertinent previous echo findings (1/2023 MML): Moderate MR, moderate LAE, mild LVE, Trace TR. LA: 2.7, LV: 3.7,

**SPECIES**

Canine

**ECHOCARDIOGRAM FINDINGS**

2D, m-mode, color flow and doppler imaging is available. Diffuse thickening of mitral valve leaflets (anterior&gt;posterior) with no prolapse into the left atrial lumen. Moderate eccentric mitral regurgitation with moderate left atrial dilation. Normal MR velocity. Mildly increased LV diameter with hyperdynamic myocardial function. The tricuspid valve appears normal, with trace tricuspid regurgitation. Normal velocity. Normal right atrial and ventricular diameter. The pulmonic and aortic valves are normal in morphology and mobility. Normal pulmonic and aortic outflow velocities. No aortic or pulmonic insufficiency. No pericardial or pleural effusion noted. No cardiac tumors observed.

**BREED**

Westie Mix

**SEX**

Male Neutered

**AGE**

8 years

**CARDIAC CHART**
**WEIGHT**

26lbs

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
<b>NORMAL PARAMETER</b>	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
<b>PATIENT</b>	5.2	2.0	1.5	1.7	34	64	0.6
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
<b>NORMAL PARAMETER</b>	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
<b>PATIENT</b>		1.0	0.8	11.8	2.8	3.7	2.3
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
<b>BODY WEIGHT DEPENDENT PARAMETERS</b>				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

**INTERPRETED BY**

 Maggie Machen Lamy,  
 DVM DACVIM  
 (Cardiology)

**IMAGING PERFORMED BY**

Kelly Reschny, RVT

**HOSPITAL NAME**

 Hawkins Animal  
 Hospital

**REFERRING VET**

Dr. Hawkins

**INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS**

Compared to the prior study, findings are persistently stable. Moderate mitral and trace tricuspid regurgitation are unchanged, without development of concurrent issues or progressive heart enlargement. No additional issues are identified.

**INVOICE**

31930

Reasonable to continue Pimobendan lifelong as prescribed with no obvious indication for additional medications. Continued assessment of progression is recommended, with a

**DATE**

7/19/23



**PATIENT**

Finley Clancy

guarded prognosis (stage B2). Patient may be at risk for development of CHF, arrhythmias, and/or sudden death going forward.

**SPECIES**

Canine

The reported blood pressure is elevated and should be reassessed for accuracy particularly given no reported clinical signs of severe hypertension (retinal changes, etc.) or evidence of LVH on echo. Ideally obtain serial measurements in a controlled, low stress environment and continue until 3 consecutive readings plateau within 5mmHg of variability. If persistently >180mmHg despite a relatively calm demeanor, recommend institution of amlodipine to effect. Additionally, if deemed accurate, screening for predisposing underlying causes of SHT is recommended (Cushing's, PLN, adrenal tumor, etc.), as primary disease is relatively uncommon and a rule out diagnosis.

**BREED**

Westie Mix

**SEX**

Male Neutered

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a progressive cough, labored breathing, exercise intolerance or collapse episodes.

**AGE**

8 years

Anesthetic risk remains mildly elevated. Cardiac protective drug choices (opioid/benzodiazepine premedication, Propofol or alfaxalone induction, iso or sevo gas) are recommended. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Judicious IV fluid rates are recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

**WEIGHT**

26lbs

**PLAN**

Reassess BP as discussed. Continue Pimobendan 0.25-0.3mg/kg PO q12h.

**INTERPRETED BY**


Maggie Machen Lamy,  
DVM DACVIM  
(Cardiology)

Recommend monitor for progression with a recheck echocardiogram in 6 months, sooner if any development of clinical signs.

**IMAGES**

**IMAGING PERFORMED BY**

Kelly Reschny, RVT



**HOSPITAL NAME**

Hawkins Animal  
Hospital

**REFERRING VET**

Dr. Hawkins

**INVOICE**

31930

**DATE**

7/19/23



**PATIENT**

Finley Clancy

The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

**SPECIES**

Canine

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

**BREED**

Westie Mix

Maggie Machen Lamy, DVM  
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)  
info@sonopath.com

**SEX**

Male Neutered

**AGE**

8 years

**WEIGHT**

26lbs

**INTERPRETED BY**

Maggie Machen Lamy,  
DVM DACVIM  
(Cardiology)

**IMAGING  
PERFORMED BY**

Kelly Reschny, RVT

**HOSPITAL NAME**

Hawkins Animal  
Hospital

**REFERRING VET**

Dr. Hawkins

**INVOICE**

31930

**DATE**

7/19/23